Overexpression of EphB4, EphrinB2, and epidermal growth factor receptor in papillary thyroid carcinoma: A pilot study

Head and Neck

Volumn 37, Issue 7, 2015, Pages 964-969

  Sharma, Giriraj K ^a   Dhillon, Vaninder K ^a   Masood, Rizwan ^a   Maceri, Dennis R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Ephb4; Ephrinb2; epidermal growth factor receptor (EGFR); gene; papillary; thyroid

Indexed keywords

BETA ACTIN; BIOLOGICAL MARKER; COMPLEMENTARY DNA; EPHRIN B2; EPHRIN RECEPTOR B4; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; EGFR PROTEIN, HUMAN;

ADULT; AGED; CANCER SIZE; CARCINOGENESIS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MALE; PILOT STUDY; PRIORITY JOURNAL; THYROID CARCINOMA; THYROIDECTOMY; UPREGULATION; WESTERN BLOTTING; CARCINOMA; DNA MICROARRAY; METABOLISM; MIDDLE AGED; PATHOLOGY; THYROID GLAND; THYROID TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA; EPHRIN-B2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PILOT PROJECTS; RECEPTOR, EPHB4; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYROID GLAND; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84931568577     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23694     Document Type: Conference Paper

References (52)

1. American Cancer Society. Cancer Facts & Figures 2012. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed January 3, 2013.
2. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
3. Sinha UK, Mazhar K, Chinn SB, et al., The association between elevated EphB4 expression, smoking status, and advanced stage disease in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132: 1053-1059.
4. Grebe SK, Hay ID,. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996; 5: 43-63.
5. Shan CX, Zhang W, Jiang DZ, Zheng XM, Liu S, Qiu M,. Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis. Laryngoscope 2012; 122: 797-804.
6. Fagin JA,. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 2004; 183: 249-256.
7. Kondo T, Ezzat S, Asa SL,. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006; 6: 292-306.
8. Jhiang SM, Sagartz JE, Tong Q, et al., Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996; 137: 375-378.
9. Knauf JA, Ma X, Smith EP, et al., Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005; 65: 4238-4245.
10. O'Neill CJ, Bullock M, Chou A, et al., BRAFV600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 2010; 148: 1139-1146.
11. Fagin JA, Mitsiades N,. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab 2008; 22: 955-969.
12. Farid NR,. P53 mutations in thyroid carcinoma: tidings from an old foe. J Endocrinol Investig 2001; 24: 536-545.
13. Asmis LM, Gerber H, Kaempf J, Studer H,. Epidermal growth factor stimulates cell proliferation and inhibits iodide uptake of FRTL-5 cells in vitro. J Endocrinol 1995; 145: 513-520.
14. Oda K, Matsuoka Y, Funahashi A, Kitano H,. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005; 1: 2005.0010.
15. Wells A,. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-643.
16. Nicholson RI, Gee JM, Harper ME,. EGFR and cancer prognosis. Eur J Cancer 2001; 37 Suppl 4: S9-S15.
17. Aasland R, Akslen LA, Varhaug JE, Lillehaug JR,. Co-expression of the genes encoding transforming growth factor-alpha and its receptor in papillary carcinomas of the thyroid. Int J Cancer 1990; 46: 382-387.
18. Akslen LA, Myking AO, Salvesen H, Varhaug JE,. Prognostic impact of EGF-receptor in papillary thyroid carcinoma. Br J Cancer 1993; 68: 808-812.
19. van der Laan BF, Freeman JL, Asa SL,. Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 1995; 5: 67-73.
20. Croyle M, Akeno N, Knauf JA, et al., RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res 2008; 68: 4183-4191.
21. Egea J, Klein R,. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol 2007; 17: 230-238.
22. Pasquale EB,. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10: 165-180.
23. Davy A, Soriano P,. Ephrin signaling in vivo: look both ways. Dev Dyn 2005; 232: 1-10.
24. Kuijper S, Turner CJ, Adams RH,. Regulation of angiogenesis by Eph-ephrin interactions. Trends Cardiovasc Med 2007; 17: 145-151.
25. Genander M, Frisén J,. Ephrins and Eph receptors in stem cells and cancer. Curr Opin Cell Biol 2010; 22: 611-616.
26. Pasquale EB,. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008; 133: 38-52.
27. Wang HU, Chen ZF, Anderson DJ,. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998; 93: 741-753.
28. Gerety SS, Wang HU, Chen ZF, Anderson DJ,. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999; 4: 403-414.
29. Wang Y, Nakayama M, Pitulescu ME, et al., Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 2010; 465: 483-486.
30. Martiny-Baron G, Korff T, Schaffner F, et al., Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 2004; 6: 248-257.
31. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB,. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A 2004; 101: 5583-5588.
32. Sawamiphak S, Seidel S, Essmann CL, et al., Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 2010; 465: 487-491.
33. Xuqing W, Lei C, Zhengfa M, et al., EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells. Tumor Biol 2012; 33: 1419-1427.
34. Kumar SR, Singh J, Xia G, et al., Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 2006; 169: 279-293.
35. Xia G, Kumar SR, Masood R, et al., EphB4 expression and biological significance in prostate cancer. Cancer Res 2005; 65: 4623-4632.
36. Nakada M, Drake KL, Nakada S, Niska JA, Berens ME,. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res 2006; 66: 8492-8500.
37. Kiyokawa E, Takai S, Tanaka M, et al., Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors. Cancer Res 1994; 54: 3645-3650.
38. Ji XD, Li G, Feng YX, et al., EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res 2011; 71: 1156-1166.
39. Vogt T, Stolz W, Welsh J, et al., Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res 1998; 4: 791-797.
40. Noren NK, Pasquale EB,. Paradoxes of the EphB4 receptor in cancer. Cancer Res 2007; 67: 3994-3997.
41. Masood R, Kumar SR, Sinha UK, et al., EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int J Cancer 2006; 119: 1236-1248.
42. Han J, Kioi M, Chu WS, Kasperbauer JL, Strome SE, Puri RK,. Identification of potential therapeutic targets in human head and neck squamous cell carcinoma. Head Neck Oncol 2009; 1: 27.
43. Liebertz DJ, Lechner MG, Masood R, et al., Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1. Head Neck Oncol 2010; 2: 5.
44. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS,. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001; 98: 1904-1913.
45. Brey EM, Lalani Z, Johnston C, et al., Automated selection of DAB-labeled tissue for immunohistochemical quantification. J Histochem Cytochem 2003; 51: 575-584.
46. Stinga AC, Margaritescu O, Stinga AS, et al., VEGFR1 and VEGFR2 immunohistochemical expression in oral squamous cell carcinoma: a morphometric study. Rom J Morphol Embryol 2011; 52: 1269-1275.
47. Yavrouian EJ, Sinha UK, Rice DH, Salam MT, Gill PS, Masood R,. The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma. Arch Otol Head Neck Surg 2008; 134: 985-991.
48. Sinha UK, Kundra A, Scalia P, et al., Expression of EphB4 in head and neck squamous cell carcinoma. Ear Nose Throat J 2003; 82: 866, 869-870, 887.
49. Casanova ML, Larcher F, Casanova B, et al., A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res 2002; 62: 3402-3407.
50. Hamada K, Oike Y, Ito Y, et al., Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 190-197.
51. Grebe SK, Hay ID,. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996; 5: 43-63.
52. Jukkola A, Bloigu R, Ebeling T, Salmela P, Blanco G,. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer 2004; 11: 571-579.